Alkermes to Acquire Avadel for Up to $2.1 Billion, Expanding Into Sleep Medicine Market

Alkermes (ALKS) announces $2.1B acquisition of Avadel Pharmaceuticals (AVDL) to gain approved narcolepsy drug Lumryz and enter the growing sleep medicine market. Deal expected Q1 2026.